OF

Orthofix Medical Inc.

OFIXHealthcareNASDAQ

Medical Devices

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$822.3M
+2.9% YoY
Net Income
-$92.2M
+26.8% YoY
EBITDA
$9.9M
+154.3% YoY
Free Cash Flow
$4.1M

Scan Results

Daily timeframe
DateIndicatorDetails
Sep 24▲ MACD Positive CrossoverHistogram +0.0596, positive momentum
Sep 23▲ MACD Positive CrossoverHistogram +0.0336, positive momentum
About Orthofix Medical Inc.

Headquartered within the healthcare sector, Orthofix Medical Inc. focuses on Medical Devices services and products. Orthofix Medical Inc., together with its subsidiaries, operates as a medical technology company in the United States, Italy, the United Kingdom, France, Germany, Brazil, and internationally. At a $399.6M market cap, Orthofix Medical Inc. ranks as a small-cap company within healthcare. It operates through two segments, Global Spine and Global Limb Reconstruction.

Where OFIX stands vs its 150-day and 200-day moving averages

As of the September 24, 2026 close, OFIX finished 16.77% below its 150-day moving average ($11.03) and 22.86% below its 200-day moving average ($11.90). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is OFIX overbought or oversold?

At the September 24, 2026 close, OFIX's RSI(14) was 45.3, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$399.6M
Fwd P/E26.51
EPS$-1.49
Beta0.62
52W Change-38.6%
Dividend Yield0.00%
ROE-13.9%
Analysis

The company holds $103.8M in cash, though total debt stands at $261.9M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Annual free cash flow of $4.1M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at -13.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $460.7M (2022) to $822.3M (2025), reflecting a 78% increase over the period.

With a beta below 0.7, Orthofix Medical Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing OFIX.

Links
More Healthcare stocks
Browse all stocks →
⚠Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms